首页> 外文期刊>British journal of ophthalmology >Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent optic neuritis not associated with demyelinating disease.
【24h】

Use of corticosteroid sparing systemic immunosuppression for treatment of corticosteroid dependent optic neuritis not associated with demyelinating disease.

机译:保留皮质类固醇的全身性免疫抑制在治疗与脱髓鞘疾病无关的皮质类固醇依赖性视神经炎中的应用。

获取原文
获取原文并翻译 | 示例
       

摘要

Aim: To describe the authors' experience and that in the published literature regarding the use of corticosteroid sparing systemic immunosuppression for patients with corticosteroid dependent optic neuritis not associated with demyelinating disease. METHODS: The records of 10 patients from the authors' clinical database, and 38 patients from the published literature with corticosteroid dependent optic neuritis, were retrospectively reviewed to determine patient demographics, diagnosis, clinical course, and outcomes. These patients had recrudescence of symptoms, such as decreased vision and pain, with attempted taper of corticosteroid. Many of these patients also suffered side effects from systemic corticosteroid use such as weight gain and uncontrolled hyperglycaemia. Antimetabolites (for example, methotrexate and azathioprine), cyclosporine and/or alkylating agents (for example, cyclophosphamide and chlorambucil) were given to enable taper of corticosteroid while effectively controlling optic neuritis. RESULTS: The study included 43 women and 5 men: 17 patients with systemic lupus erythematosus, 12 patients with sarcoidosis, 3 with other systemic autoimmune diseases, and 16 with no clinically identifiable systemic association. 79% of all patients benefited from the use of systemic immunosuppression in that they had successful corticosteroid taper, control of inflammation, improvement in symptoms, and/or tolerance of adverse effects. Mild toxicity was common and 19% of patients, most often those taking cyclophosphamide, discontinued medication because of adverse effects. 24 of 28 (86%) patients on alkylators benefited clinically, while 20 of 29 (69%) patients on antimetabolites had clinical benefit. CONCLUSION: Systemic immunosuppression may be a safer and more effective treatment alternative to chronic oral corticosteroid use in cases of corticosteroid dependent optic neuritis not associated with demyelinating disease.
机译:目的:描述作者的经验以及已发表的文献中有关皮质类固醇依赖性视神经炎与脱髓鞘疾病无关的患者使用皮质类固醇保护性全身免疫抑制的经验。方法:回顾性分析作者临床数据库中的10例患者和已发表的皮质类固醇依赖性视神经炎文献的38例患者的病历,诊断,临床过程和结果。这些患者尝试了逐渐减少的皮质类固醇激素治疗,症状复发,例如视力下降和疼痛。这些患者中的许多人还因使用全身性皮质类固醇而遭受副作用,例如体重增加和不受控制的高血糖症。给予抗代谢药(例如甲氨蝶呤和硫唑嘌呤),环孢素和/或烷基化剂(例如环磷酰胺和苯丁酸氮芥)可以使皮质类固醇逐渐减少,同时有效控制视神经炎。结果:该研究包括43名女性和5名男性:17例系统性红斑狼疮患者,12例结节病患者,3例其他全身性自身免疫性疾病和16例临床上无系统性关联的患者。所有患者中有79%受益于全身免疫抑制,因为他们具有成功的皮质类固醇锥度,炎症控制,症状改善和/或不良反应耐受性。轻度毒性反应很普遍,有19%的患者(最常见的是服用环磷酰胺的患者)由于不良反应而中止了用药。使用烷基化药的28名患者中有24名(86%)临床受益,而使用抗代谢物的29名患者中有20名(69%)具有临床受益。结论:在与非脱髓鞘疾病无关的皮质类固醇依赖性视神经炎患者中,全身免疫抑制可能是替代慢性口服皮质类固醇激素使用的更安全,更有效的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号